International Biotechnology (IBT) Competitors

GBX 1,005 0.00 (0.00%)

As of 06:48 AM Eastern

IBT vs. WWH, JFJ, ASL, TMPL, and IHP

Should you buy International Biotechnology stock or one of its competitors? MarketBeat compares International Biotechnology with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with International Biotechnology include Worldwide Healthcare (WWH), JPMorgan Japanese (JFJ), Aberforth Smaller Companies Trust (ASL), Temple Bar (TMPL), and IntegraFin (IHP). These companies are all part of the "asset management" industry.

How does International Biotechnology compare to Worldwide Healthcare?

International Biotechnology (LON:IBT) and Worldwide Healthcare (LON:WWH) are both small-cap financial services companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, risk, valuation, institutional ownership, analyst recommendations and earnings.

In the previous week, Worldwide Healthcare had 2 more articles in the media than International Biotechnology. MarketBeat recorded 3 mentions for Worldwide Healthcare and 1 mentions for International Biotechnology. Worldwide Healthcare's average media sentiment score of 1.49 beat International Biotechnology's score of -0.95 indicating that Worldwide Healthcare is being referred to more favorably in the news media.

Company	Overall Sentiment
International Biotechnology	Negative
Worldwide Healthcare	Positive

International Biotechnology pays an annual dividend of GBX 31.73 per share and has a dividend yield of 3.2%. Worldwide Healthcare pays an annual dividend of GBX 2.40 per share and has a dividend yield of 0.7%. International Biotechnology pays out -964.4% of its earnings in the form of a dividend. Worldwide Healthcare pays out -7.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. International Biotechnology is clearly the better dividend stock, given its higher yield and lower payout ratio.

Worldwide Healthcare has lower revenue, but higher earnings than International Biotechnology. International Biotechnology is trading at a lower price-to-earnings ratio than Worldwide Healthcare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
International Biotechnology	-£175K	-1,828.57	£37.91M	-£3.29	N/A
Worldwide Healthcare	-£164.31M	-7.70	£227.88M	-£30.90	N/A

Worldwide Healthcare has a net margin of 121.37% compared to International Biotechnology's net margin of -6.26%. International Biotechnology's return on equity of -0.45% beat Worldwide Healthcare's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
International Biotechnology	-6.26%	-0.45%	3.57%
Worldwide Healthcare	121.37%	-10.79%	-2.02%

International Biotechnology has a beta of 0.316, suggesting that its share price is 68% less volatile than the broader market. Comparatively, Worldwide Healthcare has a beta of 0.5136185, suggesting that its share price is 49% less volatile than the broader market.

6.9% of International Biotechnology shares are held by institutional investors. Comparatively, 8.8% of Worldwide Healthcare shares are held by institutional investors. 1.1% of International Biotechnology shares are held by company insiders. Comparatively, 0.2% of Worldwide Healthcare shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Worldwide Healthcare beats International Biotechnology on 8 of the 15 factors compared between the two stocks.

How does International Biotechnology compare to JPMorgan Japanese?

International Biotechnology (LON:IBT) and JPMorgan Japanese (LON:JFJ) are both small-cap financial services companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, dividends, institutional ownership, analyst recommendations, earnings and valuation.

In the previous week, International Biotechnology had 1 more articles in the media than JPMorgan Japanese. MarketBeat recorded 1 mentions for International Biotechnology and 0 mentions for JPMorgan Japanese. JPMorgan Japanese's average media sentiment score of 0.00 beat International Biotechnology's score of -0.95 indicating that JPMorgan Japanese is being referred to more favorably in the news media.

Company	Overall Sentiment
International Biotechnology	Negative
JPMorgan Japanese	Neutral

International Biotechnology pays an annual dividend of GBX 31.73 per share and has a dividend yield of 3.2%. JPMorgan Japanese pays an annual dividend of GBX 6.75 per share and has a dividend yield of 0.9%. International Biotechnology pays out -964.4% of its earnings in the form of a dividend. JPMorgan Japanese pays out 4.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. International Biotechnology is clearly the better dividend stock, given its higher yield and lower payout ratio.

JPMorgan Japanese has higher revenue and earnings than International Biotechnology. International Biotechnology is trading at a lower price-to-earnings ratio than JPMorgan Japanese, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
International Biotechnology	-£175K	-1,828.57	£37.91M	-£3.29	N/A
JPMorgan Japanese	£245.42M	4.94	£194.81M	£148.90	5.25

JPMorgan Japanese has a net margin of 97.91% compared to International Biotechnology's net margin of -6.26%. JPMorgan Japanese's return on equity of 21.61% beat International Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
International Biotechnology	-6.26%	-0.45%	3.57%
JPMorgan Japanese	97.91%	21.61%	8.06%

International Biotechnology has a beta of 0.316, suggesting that its stock price is 68% less volatile than the broader market. Comparatively, JPMorgan Japanese has a beta of 0.888, suggesting that its stock price is 11% less volatile than the broader market.

6.9% of International Biotechnology shares are held by institutional investors. Comparatively, 18.9% of JPMorgan Japanese shares are held by institutional investors. 1.1% of International Biotechnology shares are held by insiders. Comparatively, 0.1% of JPMorgan Japanese shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

JPMorgan Japanese beats International Biotechnology on 11 of the 15 factors compared between the two stocks.

How does International Biotechnology compare to Aberforth Smaller Companies Trust?

Aberforth Smaller Companies Trust (LON:ASL) and International Biotechnology (LON:IBT) are both small-cap financial services companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, earnings, institutional ownership, media sentiment, profitability, valuation and analyst recommendations.

In the previous week, International Biotechnology had 1 more articles in the media than Aberforth Smaller Companies Trust. MarketBeat recorded 1 mentions for International Biotechnology and 0 mentions for Aberforth Smaller Companies Trust. Aberforth Smaller Companies Trust's average media sentiment score of 1.68 beat International Biotechnology's score of -0.95 indicating that Aberforth Smaller Companies Trust is being referred to more favorably in the media.

Company	Overall Sentiment
Aberforth Smaller Companies Trust	Very Positive
International Biotechnology	Negative

13.1% of Aberforth Smaller Companies Trust shares are held by institutional investors. Comparatively, 6.9% of International Biotechnology shares are held by institutional investors. 0.3% of Aberforth Smaller Companies Trust shares are held by insiders. Comparatively, 1.1% of International Biotechnology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Aberforth Smaller Companies Trust has a net margin of 62.19% compared to International Biotechnology's net margin of -6.26%. Aberforth Smaller Companies Trust's return on equity of 6.86% beat International Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aberforth Smaller Companies Trust	62.19%	6.86%	11.67%
International Biotechnology	-6.26%	-0.45%	3.57%

Aberforth Smaller Companies Trust pays an annual dividend of GBX 44.30 per share and has a dividend yield of 2.9%. International Biotechnology pays an annual dividend of GBX 31.73 per share and has a dividend yield of 3.2%. Aberforth Smaller Companies Trust pays out 37.6% of its earnings in the form of a dividend. International Biotechnology pays out -964.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. International Biotechnology is clearly the better dividend stock, given its higher yield and lower payout ratio.

Aberforth Smaller Companies Trust has a beta of 0.925, suggesting that its stock price is 8% less volatile than the broader market. Comparatively, International Biotechnology has a beta of 0.316, suggesting that its stock price is 68% less volatile than the broader market.

Aberforth Smaller Companies Trust has higher revenue and earnings than International Biotechnology. International Biotechnology is trading at a lower price-to-earnings ratio than Aberforth Smaller Companies Trust, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aberforth Smaller Companies Trust	£99.87M	11.96	£255.01M	£117.90	12.96
International Biotechnology	-£175K	-1,828.57	£37.91M	-£3.29	N/A

Summary

Aberforth Smaller Companies Trust beats International Biotechnology on 11 of the 15 factors compared between the two stocks.

How does International Biotechnology compare to Temple Bar?

Temple Bar (LON:TMPL) and International Biotechnology (LON:IBT) are both small-cap financial services companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, profitability, earnings, media sentiment, analyst recommendations and risk.

Temple Bar has higher revenue and earnings than International Biotechnology. International Biotechnology is trading at a lower price-to-earnings ratio than Temple Bar, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Temple Bar	£281.60M	4.14	£154.90M	£97.00	3.98
International Biotechnology	-£175K	-1,828.57	£37.91M	-£3.29	N/A

In the previous week, International Biotechnology had 1 more articles in the media than Temple Bar. MarketBeat recorded 1 mentions for International Biotechnology and 0 mentions for Temple Bar. Temple Bar's average media sentiment score of 0.77 beat International Biotechnology's score of -0.95 indicating that Temple Bar is being referred to more favorably in the media.

Company	Overall Sentiment
Temple Bar	Positive
International Biotechnology	Negative

Temple Bar pays an annual dividend of GBX 14.25 per share and has a dividend yield of 3.7%. International Biotechnology pays an annual dividend of GBX 31.73 per share and has a dividend yield of 3.2%. Temple Bar pays out 14.7% of its earnings in the form of a dividend. International Biotechnology pays out -964.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

7.6% of Temple Bar shares are held by institutional investors. Comparatively, 6.9% of International Biotechnology shares are held by institutional investors. 0.4% of Temple Bar shares are held by insiders. Comparatively, 1.1% of International Biotechnology shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Temple Bar has a net margin of 82.15% compared to International Biotechnology's net margin of -6.26%. Temple Bar's return on equity of 27.93% beat International Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Temple Bar	82.15%	27.93%	7.08%
International Biotechnology	-6.26%	-0.45%	3.57%

Temple Bar has a beta of 0.57, suggesting that its stock price is 43% less volatile than the broader market. Comparatively, International Biotechnology has a beta of 0.316, suggesting that its stock price is 68% less volatile than the broader market.

Summary

Temple Bar beats International Biotechnology on 12 of the 15 factors compared between the two stocks.

How does International Biotechnology compare to IntegraFin?

IntegraFin (LON:IHP) and International Biotechnology (LON:IBT) are both small-cap financial services companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, profitability, earnings, media sentiment, analyst recommendations and risk.

IntegraFin has a beta of 1.267, indicating that its share price is 27% more volatile than the broader market. Comparatively, International Biotechnology has a beta of 0.316, indicating that its share price is 68% less volatile than the broader market.

IntegraFin has a net margin of 25.87% compared to International Biotechnology's net margin of -6.26%. IntegraFin's return on equity of 23.86% beat International Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IntegraFin	25.87%	23.86%	20.29%
International Biotechnology	-6.26%	-0.45%	3.57%

IntegraFin currently has a consensus price target of GBX 423, suggesting a potential upside of 26.65%. Given IntegraFin's stronger consensus rating and higher probable upside, equities analysts clearly believe IntegraFin is more favorable than International Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IntegraFin	0 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.60
International Biotechnology	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

IntegraFin has higher revenue and earnings than International Biotechnology. International Biotechnology is trading at a lower price-to-earnings ratio than IntegraFin, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IntegraFin	£156.80M	7.04	£52.54M	£15.50	21.55
International Biotechnology	-£175K	-1,828.57	£37.91M	-£3.29	N/A

44.1% of IntegraFin shares are owned by institutional investors. Comparatively, 6.9% of International Biotechnology shares are owned by institutional investors. 14.5% of IntegraFin shares are owned by company insiders. Comparatively, 1.1% of International Biotechnology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, IntegraFin had 1 more articles in the media than International Biotechnology. MarketBeat recorded 2 mentions for IntegraFin and 1 mentions for International Biotechnology. IntegraFin's average media sentiment score of 1.00 beat International Biotechnology's score of -0.95 indicating that IntegraFin is being referred to more favorably in the media.

Company	Overall Sentiment
IntegraFin	Positive
International Biotechnology	Negative

IntegraFin pays an annual dividend of GBX 10.50 per share and has a dividend yield of 3.1%. International Biotechnology pays an annual dividend of GBX 31.73 per share and has a dividend yield of 3.2%. IntegraFin pays out 67.7% of its earnings in the form of a dividend. International Biotechnology pays out -964.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. International Biotechnology is clearly the better dividend stock, given its higher yield and lower payout ratio.

Summary

IntegraFin beats International Biotechnology on 16 of the 18 factors compared between the two stocks.

Get International Biotechnology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IBT vs. The Competition

Export

Metric	International Biotechnology	Asset Management Industry	Financial Sector	LON Exchange
Market Cap	£320.00M	£2.37B	£5.70B	£2.75B
Dividend Yield	3.26%	5.99%	5.27%	6.07%
P/E Ratio	-305.59	25.21	16.02	365.93
Price / Sales	-1,828.57	2,084.58	1,291.14	88,337.70
Price / Cash	155.74	60.17	90.61	27.89
Price / Book	1.31	1.35	4.38	7.70
Net Income	£37.91M	£265.53M	£1.15B	£5.89B
7 Day Performance	3.01%	-0.28%	0.23%	0.42%
1 Month Performance	4.30%	2.42%	2.03%	2.10%
1 Year Performance	82.80%	13.23%	21.48%	86.90%

International Biotechnology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IBT International Biotechnology	N/A	GBX 1,005 flat	N/A	+80.8%	£319.87M	-£175K	N/A	N/A	Earnings Report
WWH Worldwide Healthcare	N/A	GBX 337.03 -1.5%	N/A	+21.5%	£1.23B	-£164.31M	N/A	N/A	Positive News
JFJ JPMorgan Japanese	N/A	GBX 785.06 +1.0%	N/A	+30.0%	£1.22B	£245.42M	5.27	N/A
ASL Aberforth Smaller Companies Trust	N/A	GBX 1,552.12 +0.0%	N/A	+4.6%	£1.21B	£99.87M	13.16	N/A	Positive News
TMPL Temple Bar	N/A	GBX 391.53 +0.4%	N/A	+26.7%	£1.18B	£281.60M	4.04	N/A

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:IBT) was last updated on 5/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

International Biotechnology (IBT) Competitors

IBT vs. WWH, JFJ, ASL, TMPL, and IHP

How does International Biotechnology compare to Worldwide Healthcare?

Summary

How does International Biotechnology compare to JPMorgan Japanese?

Summary

How does International Biotechnology compare to Aberforth Smaller Companies Trust?

Summary

How does International Biotechnology compare to Temple Bar?

Summary

How does International Biotechnology compare to IntegraFin?

Summary

Media Sentiment Over Time

IBT vs. The Competition

International Biotechnology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

International Biotechnology (IBT) Competitors

IBT vs. WWH, JFJ, ASL, TMPL, and IHP

How does International Biotechnology compare to Worldwide Healthcare?

Does the media favor IBT or WWH?

Is IBT or WWH a better dividend stock?

Which has stronger valuation and earnings, IBT or WWH?

Is IBT or WWH more profitable?

Which has more risk and volatility, IBT or WWH?

Do insiders and institutionals believe in IBT or WWH?

Summary

How does International Biotechnology compare to JPMorgan Japanese?

Does the media favor IBT or JFJ?

Is IBT or JFJ a better dividend stock?

Which has higher earnings and valuation, IBT or JFJ?

Is IBT or JFJ more profitable?

Which has more risk & volatility, IBT or JFJ?

Do insiders and institutionals believe in IBT or JFJ?

Summary

How does International Biotechnology compare to Aberforth Smaller Companies Trust?

Does the media prefer ASL or IBT?

Do insiders and institutionals believe in ASL or IBT?

Is ASL or IBT more profitable?

Is ASL or IBT a better dividend stock?

Which has more risk & volatility, ASL or IBT?

Which has better earnings and valuation, ASL or IBT?

Summary

How does International Biotechnology compare to Temple Bar?

Which has preferable valuation & earnings, TMPL or IBT?

Does the media prefer TMPL or IBT?

Is TMPL or IBT a better dividend stock?

Do institutionals and insiders believe in TMPL or IBT?

Is TMPL or IBT more profitable?

Which has more risk and volatility, TMPL or IBT?

Summary

How does International Biotechnology compare to IntegraFin?

Which has more risk & volatility, IHP or IBT?

Is IHP or IBT more profitable?

Do analysts prefer IHP or IBT?

Which has higher earnings & valuation, IHP or IBT?

Do institutionals and insiders hold more shares of IHP or IBT?

Does the media prefer IHP or IBT?

Is IHP or IBT a better dividend stock?

Summary

Media Sentiment Over Time

IBT vs. The Competition

International Biotechnology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools